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Background: Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. Frequent tumor recurrence
after surgery is related to its poor prognosis. Although gene expression signatures have been associated with outcome,
the molecular basis of HCC recurrence is not fully understood, and there is no method to predict recurrence using
peripheral blood mononuclear cells (PBMCs), which can be easily obtained for recurrence prediction in the clinical setting.
Methods: According to the microarray analysis results, we constructed a co-expression network using the k-core
algorithm to determine which genes play pivotal roles in the recurrence of HCC associated with the hepatitis B virus
(HBV) infection. Furthermore, we evaluated the mRNA and protein expressions in the PBMCs from 80 patients with or
without recurrence and 30 healthy subjects. The stability of the signatures was determined in HCC tissues from the same
80 patients. Data analysis included ROC analysis, correlation analysis, log-lank tests, and Cox modeling to identify
independent predictors of tumor recurrence.
Results: The tumor-associated proteins cyclin B1, Sec62, and Birc3 were highly expressed in a subset of samples of
recurrent HCC; cyclin B1, Sec62, and Birc3 positivity was observed in 80%, 65.7%, and 54.2% of the samples, respectively.
The Kaplan-Meier analysis revealed that high expression levels of these proteins was associated with significantly reduced
recurrence-free survival. Cox proportional hazards model analysis revealed that cyclin B1 (hazard ratio [HR], 4.762;
p=0.002) and Sec62 (HR, 2.674; p=0.018) were independent predictors of HCC recurrence.
Conclusion: These results revealed that cyclin B1 and Sec62 may be candidate biomarkers and potential therapeutic
targets for HBV-related HCC recurrence after surgery.
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Hepatocellular carcinoma (HCC) is the fifth most fre-
quent cancer and the third leading cause of cancer-
related deaths worldwide, with over a half million deaths
per annum[1]. The annual incidence of HCC in hepatitis
B cirrhotic patients can run as high as 3–5%, and one-* Correspondence: lingchangquan@hotmail.com
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reproduction in any medium, provided the orthird will develop HCC in their lifetime [2]. In China, an
endemic area with almost one third of the HBsAg car-
riers found worldwide [3]. Because of high infection
rates with hepatitis B virus (HBV), 55% of world’s HCC
cases occur in the country [4]. Surgical resection pro-
vides an opportunity for cure, but frequent recurrence
after surgery remains the major obstacle to long-term
survival [5]. It is estimated that approximately 70% of
patients will relapse within 5 years after surgery and
more than 80% of postoperative recurrence occurs in
the remnant liver [6], which can be either intrahepatic
metastasis from the primary tumor or de novo multi-
centric tumors. Typically, recurrence in HCC follows atd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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after resection, is mostly related to true metastatic
spread (i.e., early recurrence), whereas the second peak
mainly results from de novo tumors as a consequence of
the carcinogenic cirrhosis (i.e., late recurrence) [7]. Vas-
cular invasion (macroscopic and microscopic) is the
strongest predictor of recurrence although other factors
such as tumor size, number of nodules, α-fetoprotein
(AFP) levels, degree of differentiation, and satellite
lesions are also associated with recurrence [6]. Unfortu-
nately, microvascular invasion and satellites can be
assessed only with the full pathologic specimen, which
reduces the odds for an accurate preoperative prediction
of HCC recurrence. In addition to cancer, another life-
threatening condition (i.e., cirrhosis) is present in more
than 80% of patients with HCC, which renders prognos-
tic prediction a major challenge. Some clinical-based sta-
ging systems, especially the widely accepted Barcelona
Clinic Liver Cancer (BCLC) algorithm [8], establish a
road map for routine clinical decision-making. However,
these systems fail to provide molecular information,
which can complement the portrait of prognosis in com-
plex solid neoplasms. Therefore, elucidating the molecu-
lar mechanisms underlying recurrence is essential for
identifying accurate predictive biomarkers and develop-
ing effective therapeutic modalities.
To date, some cancer cell-oriented predictive systems
are neither superior to morphological classification nor
display any overlapping predictor genes, and they include
few disease-related genes [9,10]. It seems that high levels
of HBV replication contribute to the recurrence and poor
prognosis of HCC, which is linked to inflammatory cell
infiltration. Thus, the liver inflammatory response and
the whole-body immune status can largely influence the
biological behavior of HCC. Peripheral blood mono-
nuclear cells (PBMCs), the most common immune cell
subsets, are transported throughout the entire body.
Some PBMC genes may reflect behavior, especially that
of HBV-related HCC, which is closely related to the in-
flammatory response. In addition, it has been reported
that some related signals play crucial roles in cancer and
inflammation by controlling the expression of certain
cytokines [11]. These cytokines, such as IL-6, are pro-
duced by lymphocytes in liver and peripheral blood. As a
result, some characteristics of genes in PBMCs may be
related to the pathogenesis and progression of HCC.
In this study, the whole-genome Affymetrix GeneChipW
Human Genome U133 Plus 2.0 Array was applied to de-
fine a comprehensive copy number profile in PBMCs that
predicts HCC recurrence. The differentially expressed
mRNAs were then selected, validated, and subjected to
gene ontological (GO) and pathway analysis. The target
genes predominating in the gene regulatory networks
were further investigated in an attempt to provide betterunderstanding of the biological features of HCC recur-
rence. Moreover, to ensure that the signature reflecting
the profile of recurrence, we simultaneously tested the po-
tential biomarkers from 2 different kinds of patient sam-
ples, including PBMCs and cancerous tissues.
Results
Identification of recurrence-associated genes in HCC
To indentify candidate genes related to HCC recurrence, a
microarray-based gene expression profiling was analyzed.
In all, mRNA derived from 6 HCC cases (3 cases with re-
currence and 3 without recurrence) were subjected to
genome-wide analysis. The results showed that a set of 615
mRNAs were differentially expressed in HCC patients with
recurrence, among which 331 mRNAs increased and 284
mRNAs decreased, compared with those without recur-
rence (Additional file 1: Figure S1).
To further determine mRNAs involved in the cellular
behavior and signaling pathways, we conducted a GO
enrichment analysis. These 615 mRNAs were enriched
for cancer-dominant functions, such as anti-apoptosis,
cell cycle regulation, and transmembrane transport
(Figure 1A). The Kyoto Encyclopedia of Genes and
Genomes (KEGG) functional analysis of mRNAs
revealed that 10 signaling pathways were upregulated,
whereas 16 were downregulated (Figure 1B). Many of
these signaling pathways, such as antigen processing
and presentation, cell cycle, and protein export, have
been demonstrated to participate in the activation of
HCCs. Among these differentially regulated signaling
pathways, the cell cycle appeared to be the most
enriched pathway. A similar phenomenon was
observed in the GO analysis.
Furthermore, we constructed a co-expression net-
work using the k-core algorithm to determine which
gene(s) may play pivotal roles in the recurrence of
HCC according to their GO and pathway terms
(Figure 1C). Some critical genes were located in these
modules, including cycling B1 (CCNB1), SEC62 homo-
log (S. cerevisiae) (SEC62), and baculoviral IAP repeat-
containing 3 (BIRC3) (Figure 1D), which had the high-
est DiffK(i) values, suggesting that they probably play
important roles in the pathogenesis of HCC
recurrence.
To confirm the results of microarray analysis, we exam-
ined the mRNA expressions of these 3 genes using quanti-
tative real-time polymerase chain reaction (RT-PCR;
Additional file 2: Figure S2).
Elevated expression of cyclin B1, Sec62, and Birc3 in HCC
patients with recurrence
To explore whether cyclin B1, Sec62, and Birc3 are key
molecular markers in predicting HCC recurrence, we
measured the expression levels of these 3 proteins in 80
Figure 1 GO and pathway ehrichment and interaction network analyses based on the set of 615 differentially expressed genes in the
recurrent HCC and non-recurrent HCC samples. A. GO category based on the biological process for differentially expressed genes. (Upper) The
significant GO category for the upregulated genes. (Below) The significant GO category for downregulated genes. LgP is the base-10 logarithm of
the p value. B. KEGG pathway analysis for the differentially expressed genes. (Upper) The significant pathway for the upregulated genes. (Below)
The significant pathway for the downregulated genes. C. Interaction network analysis of the 615 genes. The 615 altered genes were connected in
a network based on prior known protein-protein interactions and signaling pathways. Blue, upregulated genes. Red, downregulated genes. The
CCNB1, SEC62 and BIRC3 genes had the highest DiffK(i) values; therefore, they might be of great importance to HCC recurrence in these patients.
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healthy subjects. Of the 35 recurrent HCC samples, we
found that the transcriptional and protein expressions of
cyclin B1, Sec62, and Birc3 in the PBMCs were signifi-
cantly higher than those in the non-recurrent and nor-
mal samples (p< 0.001, p< 0.001, and p< 0.001,
respectively, Figure 2A-C). However, no significant dif-
ference was found between the non-recurrent and nor-
mal samples (p= 0.581, p= 0.191, and p= 0.076,
respectively, Figure 2A-C).
To further determine the clinicopathologic significance
of cyclin B1, Sec62, and Birc3 in HCC, immunohisto-
chemical analysis was performed from 35 recurrent tis-
sues and 45 non-recurrent ones. As shown in Figure 3A
and B, the protein levels of cyclin B1, Sec62, and Birc3were substaintialy higher in the recurrent tissues than
those in the non-recurrent samples. Importantly, the
results were consistent with the transcriptional and pro-
tein results in PBMCs, which suggested that elevated ex-
pression of cyclin B1, Sec62, and Birc3 may be critical to
the recurrence of HCC.
Association of cyclin B1, Sec62, and Birc3 expression with
HCC recurrence
From ROC analysis, we found that 80%, 65.7%, and
54.2% of the patients with recurrent HCC exhibited
highly expressed cyclin B1, Sec62, and Birc3, respect-
ively. By contrast, most of non-recurrent HCC patients
had low expression levels of these proteins (p< 0.001, p
< 0.001, and p= 0.001, respectively, based on cut off
Figure 2 High expression levels of cyclin B1, Sec62, and Birc3 in the patients with recurrent HCC. A. The mRNA (left) and protein (right)
expression of cyclin B1 was significantly higher in the patients with recurrent HCC than in those with non-recurrent HCC and in the healthy
controls (p< 0.001). However, no difference was found between the non-recurrence and healthy groups (p> 0.05). B. The mRNA (left) and
protein (right) expression of Sec62 were significantly higher in the patients with recurrent HCC than those with non-recurrent HCC and in the
healthy controls (p< 0.001). However, no difference was found between the non-recurrence and healthy groups (p> 0.05). C. The mRNA (left)
and protein (right) expression levels of Birc3 were significantly higher in the patients with recurrent HCC than in those with non-recurrent HCC
and in the healthy controls (p< 0.001). However, no difference was found between the non-recurrence and healthy groups (p> 0.05). *
Compared with non-recurrence group. # Compared with the healthy group. The mRNA expression levels were quantified using quantitative PCR.
GAPDH was used as the endogenous control for the mRNA levels. The protein levels were examined by western blotting. β-actin was used as the
endogenous control for the protein levels.
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samples).
Upon clinicopathological correlation analysis, segrega-
tion of patients into the high expression of cyclin B1/
Sec62/Birc3 and low expression revealed no significant
correlations with any single clinicopathological features,
including age, sex, AFP, histopathological grading, tumornumber, or liver cirrhosis. Furthermore, we investigated
the correlation of cyclin B1, Sec62, and Birc3 expressions
with survival by univariate and multivariate survival ana-
lysis. We found that overexpression of cyclin B1, Sec62,
and Birc3 was correlated with earlier recurrence in HCC
patients who underwent surgical resection (p< 0.001, p
< 0.001, and p=0.029, respectively, Figure 4).
Figure 3 High expression levels of cyclin B1, Sec62, and Birc3 in the livers of the patients with recurrent HCC. A. Immunohistochemestry
stain for cyclin B1, Sec62, and Birc3 expression (original magnification× 400). Strong expression of these proteins was obserced in the livers of the
patients with recurrent HCC. By contrast, the expression of these proteins was apparently decreased in the patients with non-recurrent HCC. B.
cyclin B1, Sec62, and Birc3 immunohistochemical indices. The cyclin B1, Sec62, and Birc3 immunohistochemical indices were significantly higher
in the recurrent HCC samples than in the non-recurrent HCC samples. (p< 0.05). The data are mean± SD values. * p< 0.05 compared with the
non-recurrence group.
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determined the independent prognostic factors for pre-
dicting HCC recurrence (Table 1). The analysis revealed
that clinicopathological features provided significant pre-
dictive value for recurrence, including preoperative AFP
levels (p< 0.001), tumor number (p= 0.002), and liver
cirrhosis (p= 0.02), which were consistent with previous
results [12-14], suggesting that the selected samples in
this study represent the characteristics of HCC patients.
The following Cox multivariate analysis revealed that
cyclin B1 or Sec62 overexpression could be a novel inde-
pendent prognostic factor for recurrence-free survival
after surgery (cyclin B1: hazard ratio [HR], 4.762; 95%
confidence interval [CI], 1.764–12.856; p= 0.002; SEC62:
HR, 2.647; 95% CI, 1.181–6.057; p= 0.018, Table 2).Taken together, the above findings indicate that cyclin
B1 and Sec62 are important predictors of metastatic re-
currence of HCC in patients after surgery, which may
influence overall survival of patients.
Discussion
In the present study, we found cyclin B1, Sec62, and
Birc3 were aberrantly expressed proteins in HCC
patients. Highly expressed cyclin B1, Sec62, and Birc3
were associated with significantly reduced recurrence-
free survival, and cyclin B1 and Sec62 were independent
prognostic factors in this cohort. To our knowledge, this
is the first detailed systematic investigation of the expres-
sion pattern in PBMCs and the roles of these 3 proteins,
especially Sec62, in HCC recurrence.
Figure 4 The clinical significance of cyclin B1, Sec62, and Birc3 expressions in the patients with HCC surgery. Kaplan-Meier curves were
used to estimate the recurrence-free survival rates according to the expression levels of cyclin B1, Sec62, and Birc3 in the 80 HCC patients who
underwent surgery. Cyclin B1 (left), Sec62 (middle), and Birc3 (right).
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important treatment options for patients with HCC. How-
ever, tumor recurrence remains one of the major chal-
lenges for those postoperative patients. Although
increasing numbers of genes have been indentified, the
molecular mechanism of HCC metastasis and recurrence
are not fully understood. Based on the results of micro-
array analysis, cyclin B1, Sec62, Birc3 were chosen forTable 1 Univariate analyses of predictors of recurrence in
HCC patients
Variables HCC patients (n = 80)






















* Statistical analyses were conducted by Kaplan-Meier method (log rank-test).subsequent research. Cyclin B1 is known to regulate the
G2/M transition in the cell cycle. Recent studies have
demonstrated aberrant expression of cyclin B1 in several
malignant cancers, including breast cancer [15], esopha-
geal squamous cell carcinoma [16], non-small cell carcin-
oma [17], gastric cancer, and hepatocellular carcinoma
[18,19]. But it remains unclear how cyclin B1 overexpres-
sion is involved in oncogenesis and tumor progression.
Previous study demonstrated that cyclin B1 act as a prom-
ising prognostic and therapeutic target for HCC [20].
However, Chae [21] reported that the expression of cyclin
B1 had no influence on the survival of patients with breast
cancer. In the present study, elevated expressed cyclin B1
was found in the patients with recurrent HCC, contrary to
that in non-recurrent patients and healthy volunteers.
Moreover, there was no significant difference in cyclin B1
expression between the patients with non-recurrent HCC
and healthy subjects. Through the univariate analysis, cyc-
lin B1 expression was identified as an independent risk
factor for recurrence in HCC patients after surgery. This
discrepancy might be due to dissimilar expression of cyclin
B1 in different tumor types.
Similar results were observed for Sec62, which is a
member of the protein translocation apparatus in the
endoplasmic reticulum membrane. Previous studiesTable 2 Cyclin B1, Sec62 mRNA expression in HCC were
independent Predictive factors for recurrence
Variable HR (95%CI) p-value *
AFP Level
>400 ng/ml vs≤ 400 ng/ml 3.124 (1.294–7.542) 0.011
cyclin B1 expression
high vs low 4.762 (1.764–12.856) 0.002
Sec62 expression
high vs low 2.674 (1.181–6.057) 0.018
HR: risk ratio; 95% CI: 95% confidence interval; * Cox proportional hazards
regression.
Table 3 Clinicopathologic charateristics in HCC patients
Variables HCC patients(n= 80)
non-recurrence recurrence p-value *



























* p-value calculated using chi-square or Fishier exact test.
AFP, alpha-fetoprotein; BCLC, Barcelona clinc liver cancer.
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Sec62 in prostate cancer cell lines, and described
SEC62 as a potential target gene in prostate cancer
[22]. Overproduction of Sec62 is also observed in
other tumors, primarily in tumors of the lung and
thyroid [23]. In our study, it seems that Sec62 plays a
significant role in HCC recurrence. Sec62 overexpres-
sion was found in the patients with recurrent HCC.
Importantly, Sec62 was an independent risk factor for
recurrence in HCC patients after surgery as evidenced
by univariate analysis.
Although the expression of Birc3 was significantly higher
in the recurrent HCC samples than that in the non-
recurrent HCC and normal samples, a specific independ-
ent role in predicting HCC recurrence was not identified
for Birc3. Consistently, DNA amplifications of Birc2 and
Birc3 have been observed in mouse liver and human lungcancers [24,25], liver carcinoma [24], oral squamous cell
carcinoma [26,27], medulloblastoma [28], glioblastoma
[29], and pancreatic cancer [30]. The exact role of Birc3 in
HCC must be verified through a larger prospective study.
In recent years, studies on malignant tumors has pri-
marily focused on cell proliferation, migration, and
apoptosis. Cyclin B1, Sec62, and Birc3, chosen in this
study according to our microarray analysis, likely play
important roles in cell proliferation and migration. They
can exert a tumor-promoting effect on HCC by regulat-
ing cell cycle and protein translocation. In contrast to
previous studies using only HCC tissues, we examined
PBMCs and tumor tissues in the present study. Interest-
ingly, the results obtained in PBMCs were consistent
with those of the tumor tissues by immunohistochemical
analysis for. As a result, elevated cyclin B1 and Sec62 ex-
pression in PBMCs had a significantly negative prognos-
tic value in terms of recurrence-free survival, which
hints the potential use of these molecular markers to
predict the risk of tumor recurrence after surgery and to
act as therapeutic targets to reduce tumor recurrence
and improve clinical therapies.
The contribution of HBV to the current findings
must be mentioned. China is one of the highest
prevalent areas of HCC, mainly because chronic
hepatitis B carriers account for more than 10% of the
Chinese population [31]. Over 85% of patients with
HCC have HBV infection in China [32]. At present,
the studied population almost unavoidably consisted
of patients with HBV-associated HCC because of the
special situation in China. The induction of apoptosis
and stimulation of cell cycle by the HBV X protein
has been reported [33,34]. The analysis of cyclin B1,
Sec62, and Birc3 expressions in HCC patients with
other etiological backgrounds may be very useful to
ascertain the real predictive value of cyclin B1 and
Sec62 for HCC recurrence.
Despite the important roles of cyclin B1 and Sec62
in tumor recurrence and their predictive implications,
this study should be viewed as a hypothesis-
generating study. Prospective and animal studies are
needed to confirm our findings and clarify the bio-
logical effects of these proteins in more detail.Conclusions
This study demonstrates a significant association be-
tween high cyclin B1 and Sec62 expression levels and
HCC recurrence, indentifying cyclin B1 and Sec62 as
predictors of HCC recurrence. More importantly, their
expressions in the PBMCs were consistent with those
in the HCC tissues. These findings also suggest that
cyclin B1 and Sec62 might be potential molecular tar-
gets to reduce tumor recurrence.
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Cytokines and reagents
The RT reagent kit was purchased from Takara (Dalian,
China). The SYBR Green Real-Time PCR Master Mix
kit was purchased from Toyobo (Osaka, Japan). Cyclin
B1 (V152) mouse mAb and Birc3 (58 C7) rabbit mAb
were purchased from Cell Signaling Technology (Dan-
vers, MA). Sec62 (N-15) pAB sc-12324 was purchased
from Santa Cruz Biotechnology (Santa cruz, CA).
Lymphocyte separation medium (LSM 1077) was pur-
chased from PAA (MA). Trizol reagent (U.S.patent No.
5,346,994) was purchased from Invitrogen (Carlsbad,
CA).
Patient characteristics
A total of 80 HCC patients with early stage (BCLC A)
diease who underwent surgery between 2007 and 2011 in
the Changhai Hospital were enrolled in the present study.
All the subjects provided written informed consent for the
use of their blood samples and HCC tissues in accordance
with the Declaration of Helsinki, and the study protocol
was approved by our institutional review board. HCC was
diagnosed either before or after surgery and confirmed by
histopathological examination, and complete clinical and
laboratory data were available before surgery and during
follow-up. The characteristics of the HCC patients, includ-
ing age, sex, tumor size, portal vein tumor thrombi
(PVTT), BCLC, Child-Pugh, cirrhosis and preoperative
AFP levels, are shown in Table 3. Tumor differentiation
was graded by the Edmondson-Steiner grading system.
The eligibility criteria for the patients studied are as fol-
lows: (a) HCC diagnosed either before or after surgery (as
an incidental finding) and confirmed by histopathological
examination; (b) Han Chinese ethnicity; (c) the availability
of AFP level, histopathologic grading, tumor size, and
tumor number data before surgery and during follow-up;
(d) HBV-positivity and hepatitis C virus negativity; and (e)
no preoperative adjuvant antineoplastic therapy. The
follow-up course and diagnostic criteria of recurrence
have been described previously [12]. The median duration
of follow-up was 39.0 months. Using ≤12 and ≥36 months
as the cutoffs, the patients were divided into recurrence
and non-recurrence groups. In EDTA-K2 tubes, 10 mL of
anticoagulated blood were collected from HCC patients
between 6:30 and 7:00 am when they were admitted to the
Changhai Hospital. All the blood samples were used for
PBMC isolation. Microarray experiments were performed
at the Shanghaibio Corporation (National Engineering
Center for Biochip in Shanghai, China) using the Affyme-
trix GeneChipW Human Genome U133 Plus 2.0 Array
(Affymetrix, Santa Clara, CA, USA). The RNA for real-
time PCR and the protein for western blotting were pre-
pared as described previously (primers are shown in Add-
itional file 3: Table S1) [35,36].Differentially expressed probe sets
For identifying significant probe sets, the random variance
model (RVM, which is commonly used for comparisons of
more than 2 groups) T test was applied to the entire probe
sets [37]. Values of p< 0.05 and false discovery rates
< 10% were considered statistically significant.
Hierarchical cluster, GO, pathway, and GeneRel net (co-
expression network) analyses
To ascertain whether differentially expressed genes among
the groups were selected correctly, unsupervised hierarch-
ical cluster analysis was performed using 615 identified
genes. The significant genes in each unique pattern were
subjected to a GO analysis (http://www.geneontology.org/).
The GO analysis was applied to organize the genes into
hierarchical categories and uncover the co-expression net-
work according to biological process and molecular func-
tion. The co-expression network of gene interaction,
representing the critical mRNAs and their targets, was
established according to mRNA expression [38]. Mean-
while, the significant genes in unique patterns were sub-
jected to a KEGG analysis (http://www.genome.jp/kegg/),
which was performed on the basis of scoring. In detail, a 2-
sided Fisher’ exact test and a chi-square test were used to
classify the enrichment (Re) of the GO and pathway cat-
egories. The enrichment (Re) was calculated as follows:
Re ¼ nf =n
Nf =N
where nf and n represent the numbers of target genes and
total genes, respectively, in the particular GO or pathway
category and Nf and N represents the number of genes
among the entire differential corresponding target genes
and the total number of genes in the GO or pathway cat-
egories, respectively. We used gene co-expression net-
works to elucidate the interactions among the genes. Gene
co-expression Networks were built according to the nor-
malized signal intensity of specific expression genes. For
each pair of genes, we calculated the Pearson correlation
and chose the significant correlation pairs to construct the
network [39]. Within the network analysis, degree central-
ity is the simplest and most important measure to deter-
mine the relative importance of a gene within a network
[40]. The genes potentially vital to HCC recurrence were
chosen on the basis of measure differential connections be-
tween 2 networks. For the ith gene, we denoted the whole-
network connectivity in networks 1 and 2 by k1(i) and k2(i),
respectively. To facilitate the comparison between the con-
nectivity measures of each network, we divided each gene
connectivity by the maximum network connectivity as fol-
lows: K1ðiÞ ¼ k1ðiÞmaxðk1Þ and K2ðiÞ ¼
k2ðiÞ
maxðk2Þ .Next, we defined
a measure of differential connectivity as DiffK(i) =K1(i) –
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DiffK(i) increased [41].Immunohistochemistry
Immunohistochemical staining was performed as described
previously [42]. The expression levels of cyclin B1, Sec62,
and Birc3 were calculated by the number of positive cells
per 1000 hepatocytes counted, which was defined as LI. For
cyclin B1 staining, brown-stained nucleus was scored as
positive. For Sec62 staining, a brown-stained plasmalemma
was scored as positive. For Birc3 staining, brow staining in
the cytoplasm was scored as positive. The cyclin B1, Sec62,
Birc3 expressions were quantitatively evaluated using an
Olympus BH2 microscope with a computer-aided image
analysis system (QiuWei Inc, Shanghai, China). The digital
images were archived by a digital camera (Nikon 4500,
Tokyo, Japan). The positive area and optical density (OD)
of cyclin B1, Sec62, or Birc3-positive cells were determined
by measuring 3 randomly selected microscopic fields (25, 9,
10) for each slide. The immunohistochemical index was
defined as the mean integral optical density (AIOD;
AIOD=positive area×OD/total area).Data analyses
Statistical analyses were performed using SPSS version
15.0 (SPSS, Chicago, IL). The Kruskal-Wallis and Mann–
Whitney U nonparametric tests were used for the statis-
tical comparison of the variables between the investi-
gated groups. The predictive accuracy was calculated
using the ROC. The probability of recurrence-free sur-
vival was analyzed by the Kaplan-Meier method, and the
differences between the groups were estimated by the
log-rank test. Independent prognostic indicators were
assessed by multivariate analysis using Cox’s proportional
hazard model. The Pearson chi-square test or Fisher
exact test was used to compare qualitative variables, and
quantitative variables using the Spearman correlation
test. p< 0.05 (2-tailed) was considered significant.Additional files
Additional file 1: Figure S1. Unsupervised hierarchical clustering based
on the set of 615 differentially expressed genes in response to recurrent
HCC patients and non-recurrent samples. The relative gene log 2
expression changes are expressed by a color gradient intensity scale, as
shown in the upside. Green color indicates down-regulation, and red
color indicates up-regulation of gene expression. Each row represents a
separate sample and each column a single gene.
Additional file 2: Figure S2. The mRNA levels of cyclin B1, Sec62 and
Birc3 in 6 HCC patients were analysed by RT-PCR. To validate the
microarray analysis findings, we analyzed their mRNA expression using
real-time PCR in 6 samples. The expression of cyclin B1, Sec62 and Birc3
in recurrence HCC Patients were significantly higher than non-reucrrence
samples (p< 0.05). Cyclin B1 (left), Sec62 (median), and Birc3 (right). *
compared with non-recurrence group.Additional file 3: Table S1. Primers for selected genes analyzed by RT-
PCR.
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